GSE13026

Early and long-standing rheumatoid arthritis: molecular signatures identified by gene expression profiling in synovium

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

24 case / 21 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

At a given time, rheumatoid arthritis (RA) is a heterogeneous disease and its underlying molecular mechanisms is still poorly understood. Because previous microarrays studies have only focused on late RA stages, we aimed to compare the biological and molecular profiles in early and long-standing (LS) RA. Synovial biopsies obtained by arthroscopy were performed in 4 early untreated RA patients, 4 LS treated RA patients and 7 control patients. Extracted mRNA were linearly amplified and used for large-scale gene expression profiling by cDNA arrays. By gene ontology analysis, the different gene combinations obtained by comparison of early, LS RA and normal synovium were used to identify the biological processes, molecular functions and pathways involved at each stage. Three combinations of 719, 116 and 52 transcripts dissociated respectively early from LS RA patients, early or LS RA from normal synovium. We identified several gene clusters and distinct molecular signatures specifically related to early or LS RA suggesting the involvement of different pathological mechanisms at each stage. Early and LS RA have distinct molecular signatures with the participation of different biological processes during the course of the disease. These results suggest that a better knowledge of the main biological processes involved at a given RA stage might help the rheumatologist to choose the more appropriate treatment.

Overall design

PBMC then RNA were extracted from synovial biopsies of 4 eraly RA patients, 4 long-standing RA patients and from 7 normal synovium used as control. Each sample was hybridized three times in different nylon membrane.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
45 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia. Arthritis research & therapy, 2009
Available

Metadata Quality Components

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Rheumatoid arthritis Disease context came from Normalization rules.
  • Likely case group Rheumatoid arthritis 24 samples
  • Likely control group Control 21 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Disease/model vs control. Specimen: Unclear specimen/source. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Interpreted disease metadata: Rheumatoid arthritis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 19563633.
  • Publication context: Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia.. Arthritis research & therapy, 2009. PMID 19563633. DOI 10.1186/ar2744.

Cautions

  • Comparison: Disease/model vs control. Specimen: Unclear specimen/source. Comparison suitability: 0%.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Unclear specimen/source downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear specimen/source downgraded for patient tissue tumor-vs-normal search intent.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Missing or unclear metadata. Comparison - Disease/model vs control. Specimen - Unclear specimen/source. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

29 fields

Sample Group Preview

45 rows shown
Show Hide
Study totals: Case 24 | Control 21 | Unassigned 0 | Excluded 0 | Ambiguous 0 45 rows shown
Group Role Accession Title Source / characteristics Reason
Rheumatoid arthritis Case GSM326301 Early RA patient 1 - hybridization 1 Rheumatoid Arthritis patient 32 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326302 Early RA patient 1 - hybridization 2 Rheumatoid Arthritis patient 32 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326303 Early RA patient 1 - hybridization 3 Rheumatoid Arthritis patient 32 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326304 Early RA patient 2 - hybridization 1 Rheumatoid Arthritis patient 26 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326305 Early RA patient 2 - hybridization 2 Rheumatoid Arthritis patient 26 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326306 Early RA patient 2 - hybridization 3 Rheumatoid Arthritis patient 26 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326307 Early RA patient 3 - hybridization 1 Rheumatoid Arthritis patient 29 years old man Case marker detected.
Rheumatoid arthritis Case GSM326308 Early RA patient 3 - hybridization 2 Rheumatoid Arthritis patient 29 years old man Case marker detected.
Rheumatoid arthritis Case GSM326309 Early RA patient 3 - hybridization 3 Rheumatoid Arthritis patient 29 years old man Case marker detected.
Rheumatoid arthritis Case GSM326310 Early RA patient 4 - hybridization 1 Rheumatoid Arthritis patient 40 years old man Case marker detected.
Rheumatoid arthritis Case GSM326311 Early RA patient 4 - hybridization 2 Rheumatoid Arthritis patient 40 years old man Case marker detected.
Rheumatoid arthritis Case GSM326312 Early RA patient 4 - hybridization 3 Rheumatoid Arthritis patient 40 years old man Case marker detected.
Rheumatoid arthritis Case GSM326313 Long-standing RA patient 1 - hybridization 1 Rheumatoid Arthritis patient 42 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326314 Long-standing RA patient 1 - hybridization 2 Rheumatoid Arthritis patient 42 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326315 Long-standing RA patient 1 - hybridization 3 Rheumatoid Arthritis patient 42 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326316 Long-standing RA patient 2 - hybridization 1 Rheumatoid Arthritis patient 45 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326317 Long-standing RA patient 2 - hybridization 2 Rheumatoid Arthritis patient 45 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326318 Long-standing RA patient 2 - hybridization 3 Rheumatoid Arthritis patient 45 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326319 Long-standing RA patient 3 - hybridization 1 Rheumatoid Arthritis patient 42 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326320 Long-standing RA patient 3 - hybridization 2 Rheumatoid Arthritis patient 42 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326321 Long-standing RA patient 3 - hybridization 3 Rheumatoid Arthritis patient 42 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326322 Long-standing RA patient 4 - hybridization 1 Rheumatoid Arthritis patient 64 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326323 Long-standing RA patient 4 - hybridization 2 Rheumatoid Arthritis patient 64 years old woman Case marker detected.
Rheumatoid arthritis Case GSM326324 Long-standing RA patient 4 - hybridization 3 Rheumatoid Arthritis patient 64 years old woman Case marker detected.
Control Control GSM326325 Control patient 1 - hybridization 1 Control 22 years old woman Sample-local control marker detected.
Control Control GSM326326 Control patient 1 - hybridization 2 Control 22 years old woman Sample-local control marker detected.
Control Control GSM326327 Control patient 1 - hybridization 3 Control 22 years old woman Sample-local control marker detected.
Control Control GSM326328 Control patient 2 - hybridization 1 Control 26 years old man Sample-local control marker detected.
Control Control GSM326329 Control patient 2 - hybridization 2 Control 26 years old man Sample-local control marker detected.
Control Control GSM326330 Control patient 2 - hybridization 3 Control 26 years old man Sample-local control marker detected.
Control Control GSM326331 Control patient 3 - hybridization 1 Control 25 years old man Sample-local control marker detected.
Control Control GSM326332 Control patient 3 - hybridization 2 Control 25 years old man Sample-local control marker detected.
Control Control GSM326333 Control patient 3 - hybridization 3 Control 25 years old man Sample-local control marker detected.
Control Control GSM326334 Control patient 4 - hybridization 1 Control 33 years old woman Sample-local control marker detected.
Control Control GSM326335 Control patient 4 - hybridization 2 Control 33 years old woman Sample-local control marker detected.
Control Control GSM326336 Control patient 4 - hybridization 3 Control 33 years old woman Sample-local control marker detected.
Control Control GSM326337 Control patient 5 - hybridization 1 Control Age unknown, man Sample-local control marker detected.
Control Control GSM326338 Control patient 5 - hybridization 2 Control Age unknown, man Sample-local control marker detected.
Control Control GSM326339 Control patient 5 - hybridization 3 Control Age unknown, man Sample-local control marker detected.
Control Control GSM326340 Control patient 6 - hybridization 1 Control 27 years old man Sample-local control marker detected.
Control Control GSM326341 Control patient 6 - hybridization 2 Control 27 years old man Sample-local control marker detected.
Control Control GSM326342 Control patient 6 - hybridization 3 Control 27 years old man Sample-local control marker detected.
Control Control GSM326343 Control patient 7 - hybridization 1 Control 29 years old man Sample-local control marker detected.
Control Control GSM326344 Control patient 7 - hybridization 2 Control 29 years old man Sample-local control marker detected.
Control Control GSM326345 Control patient 7 - hybridization 3 Control 29 years old man Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.